Brean Murray Initiates Coverage on MedAssets (MDAS) with a Buy; Point or Transform: Something for Everyone

Article Stock Quotes (1) Comments (0)

Brean Murray initiates coverage on MedAssets (Nasdaq: MDAS) with a Buy rating. PT $25.

Brean analyst says, "Despite recovering most of its lost value, MDAS shares are still down 5% since the announced acquisition of The Broadlane Group. While we believe MDAS paid a hefty premium, we are no as concerned about the shifting growth profile."

To see all the upgrades/downgrades on shares of MDAS, visit our Analyst Ratings page.

Shares closed at $20.37 yesterday. The 52-wk range is $18.10 - 25.08

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
• UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
• Gabelli Starts Portland General Electric Company (POR) at Hold

Create E-mail Alert Related Categories

New Coverage

Related Entities

Brean Murray Carret & Co.

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?